Currently, there are 47.97M common shares owned by the public and among those 38.32M shares have been available to trade.
The company’s stock has a 5-day price change of 13.63% and 18.02% over the past three months. MIRM shares are trading 13.54% year to date (YTD), with the 12-month market performance up to 75.19% higher. It has a 12-month low price of $23.14 and touched a high of $48.89 over the same period. MIRM has an average intraday trading volume of 396.89K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 10.08%, 8.62%, and 28.62% respectively.
Institutional ownership of Mirum Pharmaceuticals Inc (NASDAQ: MIRM) shares accounts for 94.28% of the company’s 47.97M shares outstanding.
It has a market capitalization of $2.25B and a beta (3y monthly) value of 0.95. The earnings-per-share (ttm) stands at -$2.07. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.23% over the week and 3.62% over the month.
Earnings per share for the fiscal year are expected to increase by 58.79%, and 60.86% over the next financial year.
Looking at the support for the MIRM, a number of firms have released research notes about the stock. Stifel stated their Buy rating for the stock in a research note on April 17, 2024, with the firm’s price target at $48. H.C. Wainwright coverage for the Mirum Pharmaceuticals Inc (MIRM) stock in a research note released on December 18, 2023 offered a Buy rating with a price target of $58. JP Morgan was of a view on November 20, 2023 that the stock is Overweight, while Morgan Stanley gave the stock Overweight rating on November 13, 2023, issuing a price target of $60. Cantor Fitzgerald on their part issued Overweight rating on October 24, 2023.
